HomeCompareVECT vs NNN

VECT vs NNN: Dividend Comparison 2026

VECT yields 11.86% · NNN yields 5.68%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VECT wins by $18.2K in total portfolio value
10 years
VECT
VECT
● Live price
11.86%
Share price
$16.87
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43.7K
Annual income
$2,485.28
Full VECT calculator →
NNN
NNN REIT Inc.
● Live price
5.68%
Share price
$41.89
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.6K
Annual income
$2,637.42
Full NNN calculator →

Portfolio growth — VECT vs NNN

📍 VECT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVECTNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VECT + NNN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VECT pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VECT
Annual income on $10K today (after 15% tax)
$1,007.71/yr
After 10yr DRIP, annual income (after tax)
$2,112.49/yr
NNN
Annual income on $10K today (after 15% tax)
$482.93/yr
After 10yr DRIP, annual income (after tax)
$2,241.81/yr
At 15% tax rate, NNN beats the other by $129.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VECT + NNN for your $10,000?

VECT: 50%NNN: 50%
100% NNN50/50100% VECT
Portfolio after 10yr
$34.6K
Annual income
$2,561.35/yr
Blended yield
7.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

VECT
Analyst Ratings
3
Buy
Consensus: Buy
Price Target
$18.00
+6.7% upside vs current
Range: $18.00 — $18.00
Altman Z
13.9
Piotroski
4/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+7.3% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VECT buys
0
NNN buys
0
No recent congressional trades found for VECT or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVECTNNN
Forward yield11.86%5.68%
Annual dividend / share$2.00$2.38
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6%
Portfolio after 10y$43.7K$25.6K
Annual income after 10y$2,485.28$2,637.42
Total dividends collected$18.2K$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$18.00$44.93

Year-by-year: VECT vs NNN ($10,000, DRIP)

YearVECT PortfolioVECT Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$11,886$1,185.54$10,737$617.02+$1.1KVECT
2$14,034$1,316.89$11,577$710.93+$2.5KVECT
3$16,470$1,453.25$12,538$822.59+$3.9KVECT
4$19,217$1,593.89$13,645$956.06+$5.6KVECT
5$22,300$1,738.05$14,925$1,116.51+$7.4KVECT
6$25,746$1,884.96$16,415$1,310.57+$9.3KVECT
7$29,582$2,033.87$18,158$1,546.77+$11.4KVECT
8$33,837$2,184.03$20,213$1,836.20+$13.6KVECT
9$38,540$2,334.73$22,649$2,193.37+$15.9KVECT
10$43,723$2,485.28$25,558$2,637.42+$18.2KVECT

VECT vs NNN: Complete Analysis 2026

VECTStock

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.

Full VECT Calculator →

NNNREIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this VECT vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VECT vs SCHDVECT vs JEPIVECT vs OVECT vs KOVECT vs MAINVECT vs ADCVECT vs EPRTVECT vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.